Roche to Buy US-based Mirus Bio for $125mn

Swiss pharmaceutical group Roche Holdings said on Tuesday that it would pay 125 million dollars (78.5 million euros) to buy American company Mirus Bio Corporation, as it seeks to boost its portfolio.

Mirus Bio Corporation, which is based in Madison in Wisconsin, specialises in the discovery and development of technologies which are nucleic acid based.

The purchase would help Roche to reinforce its research for treatments for patients suffering from diseases ranging from cancer to metabolic disorders.

Lee Babiss, who is Roche's global head of pharma research said that with the purchase of Mirus, the group would be "at the forefront of bringing this whole new class of treatment to patients who suffer from difficult-to-treat diseases".